MarketPeel
Insider Trading Intelligence
BP

Brian T. Powl

KURA
CHIEF COMMERCIAL OFFICER · KURA ONCOLOGY, INC. · CIK 0001934232
FILING MIX · LIFETIME63%/37%
BUYS
12
SELLS
7
TOTAL VALUE
$358.7K
COMPANIES
2
ACTIVE SINCE
Jun 2022
HOLDINGS NOW
598,614
AVG SELL PX
$9.93
TRADE KIND
SHOWING 19 / 19
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 11 pending
Forward-return performance of every backtestable P/S trade by Brian T. Powl, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+60.00%+3.54%-0.58%+4.12%+1.61%
14d5+40.00%+2.30%+0.15%+2.15%+6.64%
30d5+40.00%+2.27%-0.02%+2.29%+3.02%
60d5+80.00%-1.79%-3.85%+2.06%+0.21%
90d5+40.00%-2.79%+0.42%-3.21%+4.25%
180d5(2 pending)+100.00%-16.46%+3.90%-20.36%-25.87%
1y5(4 pending)+0.00%+3.48%+15.38%-11.91%-11.91%
2y5(5 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KURA · 173,614 shares · as of May 21, 2026
050,000100,000150,000200,000202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 12 buys / 7 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KURA
KURA ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
10,000$11.00$110.0K173,614May 21, 2026May 22, 2026View →
KURA
KURA ONCOLOGY, INC.
SALE10b5-1
10b5-1 plan
339$9.21$3.1K183,614May 19, 2026May 20, 2026View →
KURA
KURA ONCOLOGY, INC.
SALE
Chief Commercial Officer
4,842$8.46$41.0K184,847Jan 27, 2026Jan 27, 2026View →
KURA
KURA ONCOLOGY, INC.
SALE
Chief Commercial Officer
1,572$8.46$13.3K183,275Jan 27, 2026Jan 27, 2026View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
100,000100,000Jan 2, 2026Jan 6, 2026View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
50,000189,689Jan 2, 2026Jan 6, 2026View →
KURA
KURA ONCOLOGY, INC.
SALE
Chief Commercial Officer
8,887$11.18$99.3K139,689Nov 14, 2025Nov 14, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
48,900148,576Nov 13, 2025Nov 14, 2025View →
KURA
KURA ONCOLOGY, INC.
SALE
Chief Commercial Officer
8,891$8.94$79.5K99,676Sep 29, 2025Sep 29, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
48,900108,567Sep 27, 2025Sep 29, 2025View →
KURA
KURA ONCOLOGY, INC.
SALE
Chief Commercial Officer
1,583$7.87$12.5K59,667Jan 28, 2025Jan 28, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
46,25061,250Jan 2, 2025Jan 6, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
92,50092,500Jan 2, 2025Jan 6, 2025View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
30,00030,000Jan 2, 2024Jan 4, 2024View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jan 2, 2024Jan 4, 2024View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
200,000200,000Aug 14, 2023Aug 16, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
425,000425,000Feb 6, 2023Feb 7, 2023View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
45,00045,000Jun 27, 2022Jun 29, 2022View →
FATE
FATE THERAPEUTICS INC
PURCHASEGRANT
Stock grant
70,00070,000Jun 27, 2022Jun 29, 2022View →
Other insiders · KURA
Loading peer insiders…
About this filer
CIK 0001934232
ROLE
Chief Commercial Officer
PRIMARY
KURA
COMPANIES
2
ACTIVE SINCE
Jun 2022
MARKETPEEL · /INSIDER/0001934232DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback